Liraglutide vs Semaglutide: Daily vs Weekly GLP-1 Drugs Compared

Liraglutide vs semaglutide compares two GLP-1 receptor agonists, both made by Novo Nordisk and both FDA-approved prescription drugs. Liraglutide, sold as Victoza for type 2 diabetes and Saxenda for weight management, is used once a day. Semaglutide, sold as Ozempic for type 2 diabetes and Wegovy for weight management, is used once a week as an injection, and it also comes as daily tablets. In the only head-to-head weight trial, STEP 8, semaglutide produced more weight loss than liraglutide. The two share the same class warnings, and liraglutide is now available as FDA-approved generics while semaglutide is not.

Peptide Labs does not sell liraglutide, semaglutide or any prescription drug. This article is general information, not medical advice. Which medicine, if any, suits a person is a decision for a licensed prescriber. For how the hormone works, see what GLP-1 is.

Liraglutide vs semaglutide at a glance

Brands: Victoza and Saxenda vs Ozempic and Wegovy

Each molecule is sold under separate brands for separate approved uses, which is the source of most confusion:

• Victoza (liraglutide, 2010): blood sugar control in adults and children 10 and older with type 2 diabetes, and lowering the risk of major cardiovascular events in adults with type 2 diabetes and heart disease.
• Saxenda (liraglutide, December 2014): long-term weight management in adults with obesity, or overweight with a weight-related condition, and in children 12 and older with obesity who weigh more than 60 kg.
• Ozempic (semaglutide, 2017): blood sugar control in adults with type 2 diabetes, plus cardiovascular and kidney risk reduction in defined groups. Not approved for weight management or for children.
• Wegovy (semaglutide, 2021): weight management in adults and children 12 and older, cardiovascular risk reduction in adults with heart disease and obesity or overweight, and a form of fatty liver disease. Wegovy tablets were approved in December 2025.
• Rybelsus and Ozempic tablets (oral semaglutide): blood sugar control in type 2 diabetes.

Victoza vs Ozempic is therefore a diabetes comparison, and Saxenda vs Wegovy a weight-management one. For the two semaglutide brands, see Wegovy vs Ozempic, and for the tablets, our guide to GLP-1 pills. Our profiles of liraglutide and semaglutide cover each molecule.

Why liraglutide is daily and semaglutide weekly

Natural GLP-1 lasts only a minute or two in the blood. Both drugs are modified versions of human GLP-1 that resist breakdown by the enzyme DPP-4. Liraglutide shares 97% of its amino acid sequence with human GLP-1, and its label gives a half-life of about 13 hours, the result of slow absorption, binding to blood proteins and stability, which makes it suitable for once-daily use at any time of day, regardless of meals. Semaglutide carries a fatty side chain whose main job, according to the Wegovy label, is binding to albumin, a blood protein; the label gives its half-life as about one week. The labels say not to combine either drug with other products containing the same molecule or with another GLP-1 receptor agonist.

Saxenda vs Wegovy: the STEP 8 head-to-head trial

STEP 8, published in JAMA in 2022, is the only randomized trial comparing the two weight-management versions directly. It enrolled 338 adults with obesity, or overweight with at least one weight-related condition, and without diabetes, at 19 U.S. sites. Everyone received diet and activity counseling, and each drug was taken at its labeled weight-management strength for 68 weeks. The comparison between the two drugs was open-label, meaning participants knew which drug they were on. The trial was funded by Novo Nordisk, which makes both drugs and was involved in its design, analysis and write-up.

The pooled placebo groups lost 1.9% on average, and the 9.4-point difference between the drugs was statistically significant.

Victoza vs Ozempic: SUSTAIN 10 and PIONEER 4

SUSTAIN 10, published in Diabetes and Metabolism in 2020, compared the two diabetes injections in 577 adults with type 2 diabetes who were already taking one to three oral diabetes drugs. It was an open-label Novo Nordisk trial run in Europe that used a common European liraglutide strength. After 30 weeks, HbA1c, a measure of average blood sugar, fell by 1.7 points with semaglutide and 1.0 point with liraglutide from an average of 8.2%, and body weight fell by 5.8 kg and 1.9 kg. Digestive side effects were reported by 43.9% on semaglutide and 38.3% on liraglutide, and 11.4% vs 6.6% stopped because of adverse events.

Oral semaglutide has also been compared with daily liraglutide. In PIONEER 4, described in the Rybelsus label, semaglutide tablets lowered HbA1c by a similar amount to liraglutide over 26 weeks, meeting the trial’s test for non-inferiority.

Cardiovascular outcome trials

Both molecules have large cardiovascular outcome trials, all funded by Novo Nordisk (LEADER also by the NIH). None compared the two drugs directly.

• LEADER (liraglutide, NEJM 2016): 9,340 people with type 2 diabetes and high cardiovascular risk, followed for a median of 3.8 years. The combined rate of cardiovascular death, nonfatal heart attack or nonfatal stroke was 13.0% with liraglutide and 14.9% with placebo.
• SUSTAIN-6 (semaglutide, NEJM 2016): 3,297 people with type 2 diabetes over 104 weeks. The same combined outcome occurred in 6.6% vs 8.9%. The trial was designed to show semaglutide was no worse than placebo; diabetic eye complications were more frequent with semaglutide.
• SELECT (semaglutide, NEJM 2023): 17,604 adults aged 45 and older with heart disease and overweight or obesity but no diabetes, followed for about 40 months. The combined outcome occurred in 6.5% vs 8.0%. This trial supports Wegovy’s cardiovascular indication.

Liraglutide side effects compared with semaglutide

Because they act on the same receptor, the two drugs share their main warnings. Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents, and both say the drugs must not be used by people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. Both warn about pancreatitis, gallbladder disease, low blood sugar when combined with insulin or a sulfonylurea, kidney injury from dehydration, serious allergic reactions and inhaling stomach contents during anesthesia or deep sedation.

The Saxenda label, revised in February 2026, lists the most common liraglutide side effects as nausea, diarrhea, constipation, vomiting, injection site reactions, headache, low blood sugar, indigestion, fatigue, dizziness, abdominal pain, raised lipase, fever and gastroenteritis. It also warns about an increase in resting heart rate, on average 2 to 3 beats per minute. Wegovy’s list is similar and adds items such as belching, bloating, reflux and hair loss. In the head-to-head trials, digestive side effects were about as common with liraglutide in STEP 8 and somewhat less common in SUSTAIN 10. Our guide to semaglutide side effects goes through that label in detail.

Generic liraglutide vs brand semaglutide

Liraglutide was the first GLP-1 drug to go generic for both of its uses. The FDA approved Hikma’s liraglutide, the first generic referencing Victoza, on December 23, 2024, for adults and children 10 and older with type 2 diabetes. In August 2025 it approved Teva’s generic of Saxenda, the first generic GLP-1 drug for weight management. Semaglutide remains brand-only in the U.S. In April 2026 the FDA gave Apotex a tentative approval for a generic of Ozempic, which means the product met the scientific requirements but cannot be marketed until patents or exclusivities allow it.

Children and teens

Liraglutide reached younger patients first. The FDA approved Victoza for children 10 to 17 with type 2 diabetes on June 17, 2019, the first GLP-1 drug approved for that group, and Saxenda for teens 12 to 17 with obesity on December 4, 2020. Wegovy was approved for teens 12 and older with obesity on December 23, 2022. Ozempic is not approved for children.

Compounded and unapproved versions

Liraglutide and semaglutide sold online as “research” products, salt forms or drops are not FDA-approved, and the FDA has warned that such products have not been reviewed for safety, effectiveness or quality. Our guide to compounded semaglutide and tirzepatide explains the compounding rules, and semaglutide vs tirzepatide compares semaglutide with the other leading weekly drug.

Frequently Asked Questions

Peptide Labs does not sell these drugs. This article is general information, not medical advice. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.

Last reviewed September 2026.

Related guides: Wegovy vs Ozempic: Same Semaglutide, Different Labels, Semaglutide Side Effects: What the Ozempic, Wegovy and Rybelsus Labels Say, What Is GLP-1? The Hormone, How GLP-1 Drugs Work and Every FDA-Approved Option, Trulicity vs Ozempic: Dulaglutide and Semaglutide Compared, Victoza Generic and Generic Saxenda: Liraglutide Explained, GLP-1 Drugs List: Every FDA-Approved Option in 2026.